Terminated × Carcinoma, Ovarian Epithelial × Carboplatin × Clear all Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
Phase 2 Terminated
26 enrolled 11 charts
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 2 Terminated
6 enrolled 9 charts
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase 1 Terminated
17 enrolled
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Terminated
7 enrolled 8 charts
Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer
Phase 2/3 Terminated
132 enrolled
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Terminated
134 enrolled
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
Phase 1 Terminated
45 enrolled
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
Phase 2 Terminated
13 enrolled 5 charts
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Phase 3 Terminated
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Phase 2 Terminated
ETC
Phase 1/2 Terminated
3 enrolled
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
Phase 3 Terminated
38 enrolled
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
Phase 3 Terminated
300 enrolled